U.S. Senator Jerry Moran has advocated for the project, noting that investments in such research are vital for maintaining national scientific leadership and improving patient outcomes. This sentiment underscores a major initiative at the University of Kansas, where a team led by Foundation
Regulatory hurdles and the complexity of characterizing nanoparticle behavior in humans have slowed the progress of bone-targeted nanomedicines. Despite these significant challenges, osteosarcoma remains a primary concern in pediatric oncology due to its high rate of metastasis and the persistent
Triple-negative breast cancer remains a significant therapeutic challenge due to its aggressive nature and the absence of common hormonal receptors. Because patients lack estrogen, progesterone, and HER2 receptors, standard endocrine therapies and HER2-targeted treatments are ineffective, leaving
Recent spectroscopy and microscopy data confirm that functionalized iron oxide particles can reach a final size of 317 nm after being loaded with chemotherapy drugs. This development marks a significant milestone in the quest to refine leukemia treatments, particularly in regions where traditional
Recent advancements in nanomedicine have positioned cellular nanodiscs as a vital innovation, yet their physical dimensions significantly dictate their therapeutic performance. These biomimetic structures, often harvested from natural cell membranes, represent a paradigm shift in how clinicians
A dual-action strategy utilizing small interfering RNA and small activating RNA provides a sophisticated framework for correcting the molecular imbalances found in complex human tumors. This innovative methodology represents a fundamental shift in modern oncology, moving away from universal,
